Bharat Biotech’s COVID nasal vaccine gets regulators gesture for holding stage 2, 3 clinical trial

Overview

• Post By :


• Source: PTI


• Date: 13 Aug,2021

The first nasal vaccine against COVID-19, developed by Bharat Biotech, has received regulator’s nod for conducting phase 2 and 3 clinical trials, the Department of Biotechnology said on Friday.

Phase 1 clinical trial has been completed in age groups ranging from 18 to 60 years, it said.

This is the first of its kind COVID-19 jab to undergo human clinical trials in India.

BBV154 is an intranasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine.